HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 6, June 2016 – Medical Devices & Healthcare Technology       » Seizing Opportunity in Asia-Pacific's Complex and Rapidly Changing Medical Device Market       » IoT in Healthcare       » High Performance Computing Cluster (HPC), Pearcey, a Result of CSIRO-Dell Partnership       » SONY Expanding Footprint in Medical Field       » Biosensors Announces Strategic Agreement with Cardinal Health       » Gene Decides How Young We Look      
INSIDE INDUSTRY
Mundipharma signs exclusive agreement with Helsinn Group for distribution of Anamorelin® across key markets in SEA

Mundipharma has entered a license agreement with Helsinn for the exclusive rights to develop, manufacture and commercialise Anamorelin®, a novel compound for the treatment of weight loss in cancer patients suffering from Non-Small Cell Lung Cancer (NSCLC) across the ten markets of Singapore, Indonesia, Malaysia, the Philippines, Brunei, Myanmar, Cambodia, Laos, Thailand and Vietnam.

Anamorelin® is a synthetic, orally active ghrelin receptor agonist that shows promise to treat cancer anorexia-cachexia in patients suffering from NSCLC. Attributed to about one-third of cancer deaths, cancer anorexia-cachexia syndrome (CACS) is a disorder that is mainly characterized by muscle atrophy and subsequent cancer induced weight loss (CIWL).

Studies have shown that there is a high correlation between CIWL and early deaths for cancer patients, with a significantly higher number of early deaths reported for patients who lost more than 5% of their body weight as compared to those who lost less than 5% of their body weight. It is estimated that over 50% of late-stage cancer patients suffer from cancer anorexia-cachexia and CIWL as a result. With no truly effective treatment available in the market today, products such as Anamorelin® will play a significant role in meeting the needs of this substantial number of patients.

"We are excited to further expand our partnership with Helsinn and supplement our portfolio of products for supportive care of patients with cancer," said Raman Singh, Regional Managing Director of Mundipharma Asia Pacific, Latin America, Middle East and Africa. "This partnership will help us in our mission to alleviate the burden of pain for cancer patients in the key markets where we operate."

Anamorelin® is currently undergoing two phase III studies, ROMANA 1 and ROMANA 2, which are running in parallel, to evaluate the efficacy of the drug in the treatment of CACS. Both of these trials are expected to complete by the end of 1H 2014.

"This partnership is another step in what we foresee as a long and fruitful association with Mundipharma. We are confident that Anamorelin® will present an important advancement in the management of cancer anorexia-cachexia," said Dr Riccardo Braglia, CEO, Helsinn Group.

Click here for the complete issue.

NEWS CRUNCH  
news Gather China & World Pharmaceutical Entrepreneurs, Create a New Chapter of Chinese Pharma Industry
news Mundipharma's New Betadine® Facility to Meet Regional Healthcare Challenges
news STRATASYS launches World's First Full-ColoUr Multi-material 3D PRINTER - THE J750 - In Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Healthcare Technology Outlook 2020 - Technology uptake
COLUMNS  
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Biomedical Imaging Technology
December:
Food Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com or Mr Edward
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy